Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierZoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Business segments
Q2 2026 · $2.28BThe company’s own SEC segment disclosure.
- Dermatology$398.0M17%
- Cattle$390.0M17%
- Anti Infective Products$244.0M11%
- Livestock$222.0M10%
- Pain Sedation$217.0M10%
- Other Pharmaceuticals$168.0M7%
- Other (8)$637.0M28%
Zoetis (ZTS) reported revenue of $2.47B in Q2 2026 (quarter ended Jun 30, 2026), down 0.2% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $691M (28% of revenue). For the full year FY2025, revenue was $9.47B (+2.3% year on year) and net income $2.67B. Its largest product in Q2 2026 was Dermatology at $398M, 17.5% of the disclosed total, just ahead of Cattle at 17.1%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry